Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study groupVolker Heinemann, Nicolas Moosmann, Daniel Oruzio et al.|Journal of Clinical Oncology|2008Cited by 14
Cetuximab + capecitabine + irinotecan (CCI) versus cetuximab + capecitabine + oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study GroupVolker Heinemann, Hermann Dietzfelbinger, Ludwig Fischer von Weikersthal et al.|Journal of Clinical Oncology|2006Cited by 11